EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies

Dominik Dannehl, Nikolas Tauber, Henning Schäffler, Sabine Heublein, Julia Lichtblau, Lisa Wisniewski, Brigitte Rack, Wolfgang Janni, Alexander Englisch, Johannes Englisch, Tobias Engler, Andreas Hartkopf, Sara Brucker, Lisbeth Hilmer, Franziska Fick, Fabian Kohls, Maggie Banys-Paluchowski, Achim Rody

Senologie - Zeitschrift für Mammadiagnostik und -therapie · 2026-09-01 · 23 (03) · 259-267

DOI: 10.1055/a-2911-1826 ↗
AbstractBibliografische Angaben

Abstract

Abstract Adjuvant endocrine therapy with CDK4/6 inhibitors necessitates regular visits, lab assessments and side effect management, currently conducted primarily at breast cancer centers in Germany. This retrospective analysis estimates the potential travel distances, times and CO2 emissions associated with centralized therapy management of adjuvant CDK 4/6 inhibitor application.Eligible patients for ribociclib or abemaciclib therapy were retrospectively identified from 5053 early breast cancer cases at the university hospitals of Ulm, Lübeck and Tübingen, using the monarchE and NATALEE criteria. Travel times were calculated assuming 24 visits over three years for ribociclib and 18 visits over two years for abemaciclib.Of the HR+/HER2− cohort, 1432 (38%) were potentially eligible for adjuvant CDK4/6 inhibitors, with 1080 patients included, based on available postal codes. Median travel distances and times for Ribociclib (3 years) were 1200 km (24.0 hours driving; 176.0 kg CO2 emissions; 50.4 hours by public transport; 72.0 kg CO2 emissions) and 900 km (18.0 hours driving; 132.3 kg CO2 emissions; 37.8 hours by public transport; 54.0 kg CO2 emissions) for abemaciclib (2 years).Despite its retrospective limitations, this analysis provides valuable insight into the impact of centralized care on travel time and CO2 emissions for oral cancer therapies in Germany. As the use of oral therapies increases, clinicians, patients, policymakers and the pharmaceutical industry should jointly develop strategies to optimize the safety, feasibility, and efficacy of oral therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →